

## **Forbion co-leads CHF 103 million investment in Noema Pharma**

- Nanna Lüneborg, General Partner at Forbion, to join Board of Directors
- Financing marks the fourth investment from Forbion's Growth Opportunities Fund II

***Naarden, The Netherlands – 07 March 2023*** – Forbion, a leading European life sciences venture capital firm, today announces that it has co-led a CHF 103 million (approx. USD 112 million) Series B financing in Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders. Noema Pharma is Forbion's fourth investment from its Growth Opportunities II fund which completed a first close of €470 million in July 2022. This second Forbion Growth Opportunities Fund invests in mostly European, later-stage biopharma companies, developing novel therapies for areas of high medical need such as CNS conditions. Nanna Lüneborg, General Partner at Forbion will join Noema Pharma's Board of Directors.

Forbion was joined by Jeito Capital as new investors in the oversubscribed financing. Also new to the syndicate were UPMC Enterprises and an undisclosed investor who were joined by existing investors Sofinnova Partners, Polaris Partners, Gilde Healthcare and Invus.

**Nanna Lüneborg, General Partner at Forbion commented:** "Noema Pharma is a prime example of how investments from our Growth Opportunities Fund II can positively impact areas of healthcare with high unmet medical needs such as CNS disorders. We have been following Noema Pharma since inception, and have been impressed by the quality and progress of its clinical pipeline and believe this is the right time to invest as the Company has started to generate very encouraging clinical data in indications of high unmet need, particularly with its lead asset, basimglurant. This is the fourth company that we have invested in from our second growth fund, and it reflects the continuing need for late-stage finance in a maturing European life sciences industry."

**Luigi Costa, Chief Executive Officer of Noema Pharma added:** "We are excited to announce the successful completion of this oversubscribed Series B financing round and very pleased to have a world-class group of investors supporting our vision of bringing much-needed treatments to those living with debilitating central nervous system disorders. We welcome our new investors who bring extensive expertise and knowledge of drug development and company building and add further strength to our robust investor base. This financing comes at a key time for Noema Pharma as we look forward to extensive news flow over the next 24 months."

Proceeds from the financing will be used to advance Noema Pharma's clinical-stage assets, including its lead compound basimglurant (NOE-101), an mGluR5 inhibitor which is being evaluated in Phase 2b clinical trials for severe pain in Trigeminal Neuralgia (TN) and seizures in Tuberous Sclerosis Complex (TSC). The Company is also developing gemlapodect (NOE-105), a PDE10a inhibitor which is being evaluated in Phase 2b clinical trials for Tourette Syndrome and Childhood Onset Fluency Disorder (COFD) or Stuttering; and NOE-115, a Phase 2 ready triple reuptake inhibitor for Atypical Depression and Binge Eating Disorder.

**-Ends-**



For more information please contact:

**Forbion and BGV**

Laura Asbjornsen

Email: [laura.asbjornsen@forbion.com](mailto:laura.asbjornsen@forbion.com)

**Consilium Strategic Communications**

Ashley Tapp, Sue Charles

Email: [forbion@consilium-comms.com](mailto:forbion@consilium-comms.com)

Tel: +44 (0)20 3709 5700

**About Forbion**

Forbion ([www.forbion.com](http://www.forbion.com)) is a dedicated life sciences venture capital firm with offices in The Netherlands, Germany and Singapore. Forbion invests in life sciences companies that are active in the (bio-) pharmaceutical space. Forbion manages well over €2.3 billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development. Forbion's current team consists of over 30 life sciences investment professionals that have built an impressive performance track record since the late nineties with successful investments in 95 companies. The firm is a signatory to the United Nations Principles for Responsible Investment. Besides financial objectives, Forbion selects investments that will positively affect the health and well-being of patients. Its investors include the EIF, through its European Recovery Programme (ERP), LfA, Dutch Venture Initiative (DVI), AMUF and EFSI facilities and KfW Capital through the Programme, "ERP – Venture Capital Fonds investments". Forbion operates a joint venture with BioGeneration Ventures (BGV), the manager of seed and early-stage funds.

**About Noema Pharma**

Noema Pharma ([www.noemapharma.com](http://www.noemapharma.com)) is a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders characterized by imbalanced neuronal networks. The Company has a well differentiated pipeline with four mid clinical-stage therapeutic product candidates in-licensed from Roche. Noema currently has 3 active Phase 2b clinical trials in highly undertreated CNS conditions: seizures in Tuberous Sclerosis Complex, severe pain in Trigeminal Neuralgia and Childhood Onset Fluency Disorder. The Company has completed a Phase 2a clinical trial in adult patients with Tourette Syndrome that is currently being extended with an adolescent cohort. The Company has also completed preclinical validation studies in Atypical Depression and Binge Eating Disorder. Noema Pharma was founded in 2019 by the leading venture capital firm Sofinnova Partners. Additional investors include Biomed Partners, Forbion, Gilde Healthcare, Invus, Jeito Capital, Polaris Partners, UPMC Enterprises, and an undisclosed investor.